Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Live attenuated vaccines in patients using TNF-alpha inhibitors
jRCTs031230070Recruiting
- Sponsor
- A grant from the National Center for Child Health and Development (2021B-9)
- Start
- May 2023
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of measles + rubella, Varicella vaccine live attenuated (Shenzhen Mellow Hope) and mumps live attenuated vaccine in measles, rubella, chickenpox and 1 more, sponsored by A grant from the National Center for Child Health and Development (2021B-9). Primary endpoint: Seropositivity rate after initial vaccination. Started May 2023; status: recruiting.
02
Drugs
measles + rubellaVaricella vaccine live attenuated (Shenzhen Mellow Hope)mumps live attenuated vaccine
03
Conditions
measlesrubellachickenpoxmumps
Beyond the preview
Go deeper on jRCTs031230070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230070.